Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 19/20 | 0.74 |
| ▸ | FGFR1 | P11362 | 10/20 | 0.74 |
| ▸ | KDR | P35968 | 10/20 | 0.74 |
| ▸ | INSR | P06213 | 5/20 | 0.74 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.67 |
| ▸ | CDK2 | P24941 | 1/20 | 0.67 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4009835 | 0.87 | IGF1R (0.69) | IGF1RFGFR1KDRINSRNTRK1 | |
| SCHEMBL3871585 | 0.86 | IGF1R (0.78) | IGF1RFGFR1KDRINSRNTRK1 | |
| SCHEMBL2121493 | 0.85 | IGF1R (1.00) | IGF1RFGFR1KDRINSRNTRK1 | |
| SCHEMBL2124412 | 0.83 | IGF1R (0.85) | IGF1RFGFR1KDRINSRNTRK1 | |
| SCHEMBL2123193 | 0.82 | IGF1R (0.78) | IGF1RFGFR1KDRINSRNTRK1 | |
| SCHEMBL3865429 | 0.81 | IGF1R (1.00) | IGF1RFGFR1KDRINSRNTRK1 | |
| SCHEMBL4016135 | 0.81 | IGF1R (0.64) | IGF1RFGFR1KDR | |
| SCHEMBL2121473 | 0.80 | NTRK1 (1.00) | IGF1RFGFR1KDRINSRNTRK1 | |
| SCHEMBL4009761 | 0.80 | IGF1R (0.60) | IGF1RFGFR1KDRINSR | |
| SCHEMBL4010342 | 0.78 | IGF1R (0.72) | IGF1RFGFR1KDRINSRNTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044063-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astra Zeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008001070-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004302-A1 | Novel Compounds | CYP11B2, CYP11B1, CYP46A1 | IGF1R 3217/4885FGFR1 1428/4885KDR 3815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.